Eris Lifesciences

ERIS

NSE

BSE

SectorHealthcare

Loading chart…

The Quarter story

The two most recent quarterly results, compared side-by-side.

ERIS Lifesciences drives strong revenue and cash growth, but margin compression and foreign selling warrant attention.

Revenue grew from ₹773 Cr to ₹873 Cr from Q1 FY26 to Q1 FY27, showing strong top-line momentum.

EBITDA margin fell from 36.4% to 33.9% from Q2 FY26 to Q1 FY27, signaling pricing and cost pressures.

EBITDA rose from ₹277 Cr to ₹296 Cr from Q1 FY26 to Q1 FY27, confirming resilient profitability.

Gross margin dropped from 76.1% to 72.6% from Q1 FY26 to Q1 FY27, reflecting tighter input costs.

Cash EPS climbed from ₹12.4 to ₹13.52 from Q1 FY26 to Q1 FY27, reflecting steady cash generation.

FPI shareholding declined from 17.18% to 14.39% from Q1 FY26 to Q1 FY27, indicating sustained foreign selling.

OCF/EBITDA improved from 65% to 77% from Q1 FY26 to Q1 FY27, highlighting better cash conversion.

Employee cost rose from ₹144 Cr to ₹153 Cr from Q1 FY26 to Q1 FY27, adding to operating overheads.

Domestic Branded Formulations revenue expanded from ₹702 Cr to ₹801 Cr from Q1 FY26 to Q1 FY27, driven by strong local demand.

DBF EBITDA margin slipped from 37.6% to 35% from Q2 FY26 to Q1 FY27, showing domestic segment margin squeeze.

About the company

Eris Lifesciences Limited is an Indian company that manufactures and markets pharmaceutical products. Founded in 2007, the company operates a manufacturing plant in Guwahati, Assam. Eris focuses on chronic, sub-chronic, and acute therapeutic areas, including cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infective. The company has a portfolio of 112 Mother Brands and a distribution network of 22 sales depots, 2,059 stockists, and over 500,000 retail chemists. Eris has expanded through acquisitions and launches of new divisions. It has five wholly-owned subsidiaries and has acquired various brands and businesses in recent years, including dermatology and cosmetology brands. The company also produces human insulin and has entered the anti-thrombotics segment.

In the news